Posts Tagged ‘Dry Eye’

Dry Eye Newbie Xiidra Grabs Large Market Share

Dry Eye Newbie Xiidra Grabs Large Market Share

During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat – if any – it would pose to Allergan’s Restasis (topical cyclosporine 0.05%). With an estimated 30 million dry eye sufferers and only 1 million or so on prescription treatment, many…

Read More

AXIM Rolls Medical Marijuana Ball in Ophthalmology

AXIM Rolls Medical Marijuana Ball in Ophthalmology

Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative effects of Alzheimer’s disease, certain seizures and chronic pain without the addictive effects of opioids. But in ophthalmology, medical marijuana has encountered the headwinds of controversy. The American Glaucoma Society…

Read More

Can Lighting Strike Twice? SARCode’s Co-Founder Gadek Takes Helm of Promising Dry Eye Start-up

Can Lighting Strike Twice? SARCode’s co-Founder Gadek Takes Helm of Promising Dry Eye Start-up - OIS Podcast - Healthegy

Three-year-old TearSolutions hopes to pen a strong sequel to SARCode’s successful tale of a start-up developing the next new treatment for Dry Eye Disease. Tom Gadek, co-founder of SARCode, developer of lifitegrast (now Shire’s potential blockbuster Xiidra), takes over the company as it begins courting partners and investors.   Transcript Tom Salemi: Hey, everybody, welcome…

Read More

Dempsey on Building the Shire Brand in Ophthalmology

Dempsey on Building the Shire Brand in Ophthalmology - OIS Podcast - Eye On Innovation

Robert Dempsey, vice president of ophthalmics at Shire, was charged with building a brand in ophthalmology with no new drugs. Two years later, Shire has – in the words of one physician – one of “the best kept secrets” in eye care. Dempsey explains how Shire came to build something from nothing. Podcast Guest Robert…

Read More

LacriScience Enters Next Chapter

Chris D. Geddes, Ph.D, and Paul Gavaris of LacriScience share the prototype of the LacriPen, a handheld, portable, diagnostic tool that measures osmolarity to within 2 mOsml and can detect other viruses and bacteria including Methicillin-resistant Staphylococcus aureus (MRSA). Highlights 00:24 – “This has been a pivotal moment.” 00:53 – “We’ve had a lot of traction…

Read More

TearScience Pivots to Focus on Early-Stage OSD

TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands, President and CEO Joseph Boorady, OD, told OIS@ASCRS 2016. Dr. Boorady himself is…

Read More

TearLab Targets Multiple Biomarkers in Dry Eye

A physiologically stable ocular surface is a big determinant in cataract and refractive surgery outcomes, so TearLab Corp. is looking to build out its lab-on-a-chip platform to evaluate the ocular surface for additional biomarkers, CEO Seph Jensen told the panel on diagnostics and the premium channel at OIS@ASCRS 2016. The TearLab Osmolarity Test, for diagnosing…

Read More

New CEO Boorady Explains TearScience’s Strategic Shift

TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands. Highlights 00:39 – When did you join TearScience and what changes did you…

Read More

OISPodcast@ASCRS – Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise

OISPodcast@ASCRS - Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise - OIS Podcast - Eye On Innovation

Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business in ophthalmology. Bill Meury, the newly named chief commercial officer of Allergan, talks about the non-Pfizer deal, Allergan’s ophthalmology pipeline and where…

Read More

2016 Promises to Disrupt Dry Eye

Drugs & Devices for Dry Eye - Ophthalmology Innovation Summit 2015

This year promises to deliver disruption to the dry eye disease market as companies work to roll out new drugs, devices, and diagnostics. Shire may deliver the biggest success. The company is close to bringing a second therapeutic to the market to treat dry eye conditions, as lifitegrast is currently awaiting US regulatory approval. If…

Read More